MSHL: Summary for Marshall Edwards, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:09am EST - Canadian Markets open in 3 hours and 21 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Marshall Edwards Inc. (MSHL)

On Feb 9: 0.56 USD 0.00 (0.00%)

MORE ON MSHL

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Marshall Edwards, Inc. (NGM:MSHL) Delayed quote data

Last Trade:	0.56 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	0.56
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	N/A

Day's Range:	N/A - N/A
52wk Range:	0.25 - 1.74
Volume:	0
Avg Vol (3m):	50,779.4
Market Cap:	41.14M
P/E (ttm):	N/A
EPS (ttm):	-0.15
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add MSHL to Portfolio

Download Data

HEADLINES

•	MARSHALL EDWARDS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Tue 4:47pm)

•	Marshall Edwards, Inc.'s Action Intended to Regain Compliance With Nasdaq Share Price Rule, Benefit Shareholders
	Marketwire (Tue 3:30pm)

•	Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
	Marketwire (Mon, Feb 8)

•	Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
	Marketwire (Thu, Jan 21)

•	MARSHALL EDWARDS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Wed, Dec 2)

•	Marshall Edwards, Inc. Appoints Acting CEO
	Marketwire (Tue, Dec 1)

•	MARSHALL EDWARDS INC Financials
	EDGAR Online Financials (Tue, Nov 17)

•	MARSHALL EDWARDS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 12)

•	Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
	Marketwire (Tue, Sep 29)

•	MARSHALL EDWARDS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa
	EDGAR Online (Tue, Sep 22)

More Headlines for MSHL...

ANALYST

EPS Est (next year) (Dec-69) :	N/A
EPS Est (in 2 years) (Dec-69) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia.

Full Company Profile

Add to Portfolio

Email to a Friend

•